Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Other Operating Expenses (2017 - 2025)

Historic Other Operating Expenses for Teva Pharmaceutical Industries (TEVJF) over the last 9 years, with Q4 2025 value amounting to -$3.0 million.

  • Teva Pharmaceutical Industries' Other Operating Expenses rose 6250.0% to -$3.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$19.0 million, marking a year-over-year decrease of 23571.43%. This contributed to the annual value of -$18.0 million for FY2025, which is 22857.14% down from last year.
  • Teva Pharmaceutical Industries' Other Operating Expenses amounted to -$3.0 million in Q4 2025, which was up 6250.0% from -$7.0 million recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Other Operating Expenses ranged from a high of $52.0 million in Q1 2022 and a low of -$8.0 million during Q4 2024
  • Its 5-year average for Other Operating Expenses is $12.5 million, with a median of $5.5 million in 2021.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first soared by 94000.0% in 2022, then crashed by 40000.0% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Other Operating Expenses stood at $25.0 million in 2021, then decreased by 24.0% to $19.0 million in 2022, then plummeted by 68.42% to $6.0 million in 2023, then plummeted by 233.33% to -$8.0 million in 2024, then surged by 62.5% to -$3.0 million in 2025.
  • Its last three reported values are -$3.0 million in Q4 2025, -$7.0 million for Q3 2025, and -$4.0 million during Q2 2025.